
Biogen, Eisai's Leqembi wins EU authorization for some patients
European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage patients “under strict conditions.” The decision from the … Sign up to read this article for free. Get free access …